This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, and takes a look at two favorite health-care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a big pharma shockingly stopped the FDA from reviewing its newest diabetes drug.
In this video, health-care analysts David Williamson and Max Macaluso discuss Gilead's (GILD 0.23%) new drug application for idelalisib, which treats Non-Hodgkin's Lymphoma. Watch and find out how it stacks up against its competition, its sales potential, and its overall importance to the big biotech.
Follow David on Twitter: @MotleyDavid.
